(Q58030146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

main subject

phase I clinical trial

1 reference

1 reference

Vaishali Sanchorawala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Giampaolo Merlini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Giovanni Palladini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

S W Dubrey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

D E Reece

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

U Hegenbart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J-P Fermand

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R A Vescio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J Bladé

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

L T Heffner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

H Hassoun

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

X Liu

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

C Enny

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

P Ramaswami

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Y Elsayed

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

H Van De Velde

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S Mortimer

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Cakana

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R L Comenzo

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Velcade Can2007 Study Group

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

13 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

QJM: An International Journal of Medicine

7 February 2020

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

957-970

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

21 January 2018

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Resolution of heart failure in patients with AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Amyloidosis: is a cure possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Guidelines on the diagnosis and management of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Current treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

21 January 2018

New drugs for myeloma

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Cardiac amyloidosis responding to bortezomib: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Management of patients with malignant ventricular arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Electrocardiographic arrhythmia risk testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCR105

21 January 2018

Identifiers

DOI

10.1093/QJMED/HCR105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21752867%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference